Equities research analysts expect that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will report sales of $6.63 million for the current fiscal quarter, according to Zacks. Three analysts have made estimates for BioCryst Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $3.39 million and the highest estimate coming in at $9.20 million. BioCryst Pharmaceuticals reported sales of $8.98 million in the same quarter last year, which would suggest a negative year over year growth rate of 26.2%. The company is expected to report its next quarterly earnings report on Monday, February 26th.
On average, analysts expect that BioCryst Pharmaceuticals will report full-year sales of $6.63 million for the current fiscal year, with estimates ranging from $21.50 million to $30.50 million. For the next year, analysts expect that the business will post sales of $21.34 million per share, with estimates ranging from $6.00 million to $35.19 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for BioCryst Pharmaceuticals.
Several equities analysts recently commented on the company. BidaskClub upgraded BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, January 23rd. Royal Bank of Canada upgraded BioCryst Pharmaceuticals from a “sector perform” rating to an “outperform” rating and set a $6.00 price objective on the stock in a research note on Tuesday, January 2nd. Finally, Barclays initiated coverage on shares of BioCryst Pharmaceuticals in a report on Wednesday, December 20th. They set an “equal weight” rating and a $6.00 target price on the stock. Two analysts have rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company’s stock. BioCryst Pharmaceuticals has an average rating of “Hold” and a consensus target price of $8.63.
A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. raised its holdings in BioCryst Pharmaceuticals by 15.0% during the 4th quarter. BlackRock Inc. now owns 7,614,280 shares of the biotechnology company’s stock valued at $37,386,000 after acquiring an additional 993,100 shares during the period. Vanguard Group Inc. raised its holdings in BioCryst Pharmaceuticals by 19.9% during the 2nd quarter. Vanguard Group Inc. now owns 6,007,815 shares of the biotechnology company’s stock valued at $33,404,000 after acquiring an additional 996,052 shares during the period. Janus Henderson Group PLC bought a new position in shares of BioCryst Pharmaceuticals in the third quarter worth $23,762,000. State Street Corp increased its holdings in shares of BioCryst Pharmaceuticals by 72.0% in the second quarter. State Street Corp now owns 3,909,013 shares of the biotechnology company’s stock worth $21,736,000 after purchasing an additional 1,636,909 shares during the period. Finally, VHCP Management II LLC increased its holdings in shares of BioCryst Pharmaceuticals by 27.9% in the third quarter. VHCP Management II LLC now owns 3,165,457 shares of the biotechnology company’s stock worth $16,587,000 after purchasing an additional 690,290 shares during the period. 84.79% of the stock is currently owned by institutional investors and hedge funds.
WARNING: This story was originally posted by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/02/12/biocryst-pharmaceuticals-inc-bcrx-expected-to-post-quarterly-sales-of-6-63-million.html.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.